Evidence map›Paper›PMID 40410431›Full record

ArticleScientific reports2025

Taurine as a supplement for treating type II diabetes mellitus with metformin and DPP4 inhibitor.

Tianyichen Xiao, Caiming Wu, Yuxuan Huang, Fangping Zheng, Nafen Li, Weihong Yan, Chengyao Li, Qida He, Wenbin Hong, Siqi Wu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tianyichen XiaoState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Caiming WuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Yuxuan HuangXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Fangping ZhengXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Nafen LiXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Weihong YanXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Chengyao LiXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Qida HeXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Wenbin HongState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Siqi WuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Yulong LiState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Songqing WangState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Lei ZhangState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China.
Changqin LiuDepartment of Endocrinology and Diabetes and Fujian Province Key Laboratory of Diabetes Translational Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, China. liuchangqin@126.com.
Tianwei LinState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs From Natural Products, School of Life Sciences, Xiamen University, Xiamen, China. twlin@xmu.edu.cn.
Xueqin ChenXiamen Key Laboratory of Clinical Efficacy and Evidence Studies of Traditional Chinese Medicine, Department of Traditional Chinese Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China. xqchen@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients of type 2 diabetes mellitus (T2DM) were grouped into subtypes by a symptom-based diagnostic system of the traditional Chinese medicine for detecting metabolomic information that would otherwise be lost due to the high degree of variations in clinical samples. LC/MS-based metabolomic tools were employed to identify distinct metabolomic features in T2DM patients in one of the subtypes in the symptom-based diagnostic system. Several of the affected metabolic pathways could be ameliorated by the combined treatment of metformin and DPP4 inhibitor, except the taurine/hypotaurine metabolic pathway. It was possible that modulating the taurine/hypotaurine metabolism in the combined treatment with metformin and DPP4 inhibitor would enhance the therapeutic effects. To this end, a mouse diabetic model was treated with taurine in addition to metformin and DPP4 inhibitor. Indeed supplementing taurine during the combined treatment led to improvements in various indicators of the disorder such as those for the fatty acid and glucose metabolisms. It could be concluded that taurine was a useful supplement for treating T2DM with metformin and DPP4 inhibitor.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminTaurineAnimalsDiabetes Mellitus, ExperimentalDietary SupplementsDrug Therapy, CombinationFemaleHumansMaleMiceMiddle AgedDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminTaurineDPP4 inhibitorMetforminSyndrome differentiationTaurineType 2 diabetes mellitus

Identifiers

PMID40410431
PMCPMC12102206

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.